Wogonoside seems to alleviate colitis by protecting against intestinal barrier dysfunction through the reinforcement of tight junctions via regulation of the MLCK/pMLC2 signaling pathway in Caco2 cells 105, whereas in DSS-induced UC mice this compound seemed to lead to dual inhibition of NF-κB and NLRP3 inflammasome 106. This evidence concerns the gene NLRP3 and colitis.